R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts
Primary AML patient somatic mutation analysis to determine variable allele frequency for the study of repurposing FDA approved PARP inhibitors for patients that carry spliceosome mutations by exploiting R-loop dependent vulnerabilities arising from RNA splicing perturbations